Sam Agresta, M.D.

Chair:  Sam Agresta, M.D., Infinity Board Member and Chief Medical Officer of Foghorn Therapeutics. Previously Dr. Agresta was responsible for the development and approval of several important drugs including of TIBSOVO® and IDHIFA® for patients with IDH1 and IDH2 mutation positive AML while at Agios Pharmaceuticals and, while at Genentech, he played a key role in the global development of KADCYLA®, which is approved for HER2 positive breast cancer. Dr. Agresta also played a key role in designing the Infinity trials now underway and is actively engaged with the company in advancing these trials.

Toni Choueiri, M.D.

Toni Choueiri, M.D., Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute/Brigham and Women’s Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School is a recognized thought leader in the GU field who has done extensive work in the development of better treatments for patients with RCC. Choueiri is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and past President of the Medical Staff at Dana-Farber (2016-2018).

Dr. Choueiri works on the development of novel experimental therapies and biomarkers in GU malignancies, including Kidney Cancer. His work has led to the approval of several treatments in kidney cancer such as cabozantinib, avelumab and others.  His work has been published in journals such as the New England Journal of Medicine, Nature, Science, Cancer Cell, Journal of American Medical Association, Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, and many others. He lectures frequently throughout the United States and around the world. He has over 500 PubMed-listed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.  Dr. Choueiri will bring great insight to the interpretation of our data from MARIO-3 in RCC and the development of next steps.

Michael Postow, M.D.

Michael Postow, M.D., is Co-Lead Melanoma Disease Management Team at Memorial Sloan Kettering Cancer Center and assistant professor of medicine at Weill Cornell Medical College. Dr. Postow treats patients with advanced melanoma and was the principal investigator of a clinical trial which led to FDA approval of the nivolumab + ipilimumab immunotherapy combination to treat melanoma. He has published first or senior author publications related to melanoma and immunotherapy in the New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology and speaks at US and international meetings about topics related to research and treatment of advanced melanoma.

Dr. Postow is currently leading clinical trials testing new immunotherapy combinations in patients with advanced melanoma, including as an investigator on Infinity’s MARIO-1 trial of IPI-549 in combination with Opdivo for which he brings tremendous insight in treating patients and into potential future paths for IPI-549 in melanoma.

Padmanee (Pam) Sharma, M.D., Ph.D.

Padmanee (Pam) Sharma, M.D., Ph.D., is co-leader of MD Anderson’s immunotherapy platform and C. and Jeanette Hsu Endowed Chair in Cell Biology, and currently holds Dual/Joint/Adjunct Appointments as Professor in the Department of Genitourinary Medical Oncology and Professor in the Department of Immunology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center.

Dr. Sharma specializes in renal, bladder and prostate cancer. Her prime focus is to understand the mechanisms and pathways within the immune system responsible for tumor rejection. Since 2005 she has been a principal investigator for several clinical trials launched to improve the efficacy of cancer immunotherapies. Notably, Dr. Sharma was the principal investigator on the BMS Checkmate 275 study that first demonstrated the association of high MDSCs to significantly lower overall survival in patients with UC and which provide the inspiration for our MARIO-275 study for which her unique insights will be invaluable.